| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
QTREX Quantum Ltd.$1.9
-0.13 (-6.49%)
Market Cap
31.68 M
EPS
-0.45
P/E Ratio
-
Value Trade
46.19 M
89.42 %
Week
27.52 %
1 Month
29.31 %
3 Month
-20.88 %
6 Month
-85.46 %
5 Year
-85.46 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
9.16 M
52 Week Range
0.28 - 1.65
% held by Insiders
2.26 %
% held by Institutions
14.69 %
Enterprise Value
29.99 M
Total Shares
43.27 M
Short %
22.8 %
Float Shares
36.04 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in QTEX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
QTREX Quantum Ltd. (QTEX) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
QTEX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
QTEX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
QTEX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
QTEX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
QTEX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
QTEXQTREX Expands into Quantum Processor Interface with Single-Build Cryogenic Chip Carrier Based on a design supplied by a major U.S.-based technology company active in quantum computing, the milestone extends QTREX's AME p
QTREX Quantum Ltd. has achieved a significant milestone by producing a cryogenic chip carrier using its proprietary single-build AME process, following a design from a major U.S. technology company. This innovation expands QTREX's involvement within the quantum hardware ecosystem, integrating the chip carrier with the interconnect structure in one architecture. The new capability is expected to enhance signal transport and critical functions around quantum processors, positioning the company to address scaling challenges in future quantum computing systems. QTREX plans to showcase the chip carrier sample during Quantum.Tech World 2026 and tailor designs for specific customer requirements.
Read more →QTEXQTREX Awarded Government Grant to Advance the World's First Native RF Dielectric Material for Quantum Computing Nes Ziona, Israel
QTREX Quantum Ltd. has received a grant of approximately $1 million from the Israel Innovation Authority to develop a native RF dielectric material specifically designed for scalable superconducting quantum computing. This material aims to address critical challenges in radio frequency signal routing in cryogenic environments. The grant supports QTREX's vision of advancing its integration of materials and electronics to meet the unique demands of quantum connectivity. CEO Dagi Ben-Noon emphasized that conventional wiring architectures are inadequate for the scaling needs of superconducting quantum processors, underscoring the need for purpose-built solutions in the industry.
Read more →QTEXQTREX Secures Purchase Order from a U.S.-based Fortune 500 company for an AME System and Related Materials Nes Ziona, Israel
QTREX Quantum Ltd. has announced a purchase order from a Fortune 500 company for an Additively Manufactured Electronics (AME) system and related materials. This order is expected to enhance QTREX's commercial footprint in the AME sector, reinforcing its position in advanced technology environments. The AME system will be delivered outside the United States, aiming to provide unique manufacturing capabilities that traditional technologies cannot achieve. CEO Dagi Ben-Noon emphasized the advantages of the AME platform, highlighting the company's growing commercial activity and engagement with tier-1 customers.
Read more →QTEXQTREX Announces Pricing of a $10 Million Private Placement of Ordinary Shares with a New Fundamental Institutional Investor Nes Ziona, Israel
QTREX Quantum Ltd. has announced a $10 million private placement agreement with a fundamental institutional investor for 6,666,667 ordinary shares. The company plans to use the proceeds for working capital and general corporate purposes. The closing of the offering is anticipated around June 1, 2026. Company CEO Dagi Ben-Noon expressed optimism about this funding reinforcing their transition into a quantum hardware infrastructure company and advancing their additively manufactured electronics capabilities.
Read more →QTEXAdditively Manufactured Electronics and Fabrica Product Lines (Product Lines of Nano Dimension Ltd.) Combined Abbreviated Financial Statements
QTREX Quantum Ltd. has undergone an audit of its financial statements related to the acquisition of certain assets and liabilities from Nano Dimension Ltd.'s Additively Manufactured Electronics and Fabrica product lines. The financial statements reveal a decline in revenues and assets, with significant losses and expenses reported for the years ending December 31, 2024 and 2025. There is considerable uncertainty surrounding the continued viability of the Acquired Operations due to ongoing financial losses and dependence on financial support from the acquiring company.
Read more →QTEXInspira Technologies to Begin Trading as QTREX Quantum Under Nasdaq Ticker "QTEX" on
Inspira Technologies will start trading under the new ticker symbol 'QTEX' on May 20, 2026, as part of its corporate rebranding to QTREX Quantum Ltd. This change emphasizes the company's strategic focus on its Additively Manufactured Electronics platform, targeting improvements in quantum connectivity infrastructure. The rebranding aligns with Inspira's commitment to developing high-performance electronics solutions for sectors including defense and aerospace. Existing shareholders won't need to take any action during this transition.
Read more →QTEXNYU Langone Issues $580,000 Purchase Order for Inspira's FDA-Cleared ART100 Following Multi-Patient Hospital Evaluation RA'ANANA, Israel
Inspira Technologies has received a $580,000 purchase order from NYU Langone Hospital for its FDA-cleared ART100 extracorporeal blood circulation systems. This order follows a successful evaluation involving over 30 patients, affirming ART100's operational value in clinical settings. The purchase order marks a transition from evaluation to commercial procurement and enhances Inspira's position in ongoing discussions with other hospital systems. ART100 is currently under evaluation in additional hospitals across the U.S.
Read more →QTEXTechnologies CEO Issues Letter to Shareholders on Strategic Direction and Value Creation Plan
Inspira Technologies has issued a letter from CEO Dagi Ben-Noon outlining a comprehensive strategic direction focused on value creation through its Additively Manufactured Electronics (AME) platform and quantum connectivity initiatives. The Company is shifting its operations from legacy medical activities to prioritize scalable revenue generation in high-demand sectors. Recent commercial achievements demonstrate significant interest and ongoing engagements with Tier-1 technology and defense customers. The move to rebrand as QTREX Quantum Ltd. aligns with its ambitious plans within the rapidly evolving quantum computing market.
Read more →QTEXInspira Secures $596,000 AME System Order from Leading Irish Technological University RA'ANANA, Israel
Inspira Technologies has announced a $596,000 purchase order for its Additively Manufactured Electronics (AME) system from a prominent Irish technological university. This order, which includes a 40% non-refundable upfront payment, aims to support the university's advanced research in various cutting-edge domains. The deployment of the system is set to provide Inspira with a recurring revenue model through proprietary consumables and services, reinforcing its commercial strategy. The installation will also serve as a reference point for fostering future engagements with academic and commercial institutions across Europe.
Read more →QTEXInspira and Qarakal Sign Joint Development Agreement
Inspira Technologies has entered into a Joint Development Agreement with Qarakal Quantum to enhance the performance of superconducting quantum systems. This collaboration focuses on testing Inspira's Additively Manufactured Electronics platform under cryogenic conditions, which is crucial for improving signal connectivity in quantum computing. The structured agreement includes a multi-phase engineering program that aims to address significant challenges in scaling quantum technology. This partnership is a strategic move for Inspira as it expands its capabilities within the quantum computing sector.
Read more →QTEXInspira Technologies Secures Fully Paid $390,000 Purchase Order and Recurring Revenue Stream from Premier APAC University RA'ANANA, Israel
Inspira Technologies has secured a fully paid purchase order worth $390,000 for its additive manufacturing electronics system from a leading Asia-Pacific university. This agreement not only provides immediate revenue but also establishes a recurring revenue stream through consumables and service fees. The AME system is designed to support advanced quantum research, facilitating the development of high-performance electronics crucial for scaling quantum computing systems. Delivery and deployment of the system are scheduled in the coming weeks, accompanied by tailored training for the university's research teams.
Read more →QTEXInspira Completes Commercial Deployment of its
Inspira Technologies OXY B.H.N. Ltd. announced the successful deployment of its Additively Manufactured Electronics (AME) system at a Tier-1 U.S. defense customer site. This milestone is seen as a significant achievement that confirms the demand for the AME platform in advanced defense operations and establishes a contractual basis for ongoing revenue. Although the identity of the customer remains undisclosed due to confidentiality, the engagement highlights the strategic importance of Inspira's technology in sectors like quantum computing and superconducting systems. The company expresses optimism about its financial future as this deployment could enhance its growth trajectory.
Read more →QTEXTechnologies Appoints Yoav Rozanovich as Chief Business Officer to Drive Immediate Revenue Growth and Quantum Expansion
Inspira Technologies has appointed Yoav Rozanovich as Chief Business Officer to lead its commercial strategy. His experience in additive manufacturing and advanced electronics is anticipated to drive immediate revenue growth and long-term success in the quantum computing sector. The company aims to take advantage of existing assets and industry relationships to create scalable revenue opportunities, especially following the acquisition of the Additive Manufacturing of Electronics business from Nano Dimension. This strategic hiring reflects Inspira's transition from planning to active commercial execution.
Read more →QTEXto the Company's Report of Foreign Private Issuer on Form 6-K, filed with the SEC on
Inspira Technologies Oxy B.H.N. Ltd. is scheduled to hold an Extraordinary General Meeting of Shareholders on May 6, 2026. The Board unanimously supports Proposal 1, which includes a potential name change to QTREX Ltd. Shareholders eligible to vote must be recorded by April 21, 2026, and can utilize proxies to participate. Important timelines for submitting additional agenda items and Position Statements are also provided, ensuring robust shareholder engagement.
Read more →QTEXInspira Enters Quantum Computing Sector, Targeting a Critical Connectivity Bottleneck with Newly Acquired AME Platform The Company is targeting a new 3D connectivity architecture for use in dilution cryostats, designed t
Inspira Technologies has announced its entry into the quantum computing sector by acquiring an additive manufactured electronics platform aimed at addressing critical connectivity challenges in dilution cryostats. The new 3D connectivity architecture is designed to enhance the stability and performance of quantum systems. With over $200 million invested in AME technology, Inspira is well-positioned to leverage its expertise and industry connections to pursue collaborations in the quantum space. The company aims to maintain its focus on existing medical initiatives while transitioning to a new corporate identity aligned with its quantum computing strategy.
Read more →QTEXInspira Technologies Announces Acquisition of
Inspira Technologies has announced the acquisition of the AME platform from Nano Dimension, which includes key intellectual property, advanced engineering capabilities, and various commercial assets. The acquisition is valued at up to $12.5 million, with an upfront payment of $2 million and additional performance-based payments. This move is aimed at enhancing Inspira's strategic position in high-value electronic applications as the company continues its existing medical business operations independently. A further strategic update is anticipated soon, highlighting the company's plans moving forward.
Read more →QTEXTechnologies Terminates ATM and SEPA Equity Facilities to Prepare for Next Strategic Phase
Inspira Technologies has announced the termination of its sales agreement with A.G.P./Alliance Global Partners and its Standby Equity Purchase Agreement with YA II PN, Ltd. The decision to end these financing facilities is aimed at maintaining a disciplined capital structure as the company prepares for its next strategic phase. Inspira is focusing on its commercial-stage medical device offerings, including the FDA-cleared INSPIRA ART100 system and the upcoming INSPIRA ART500. The company's advancements in proprietary blood monitoring technologies further strengthen its position in the life-support and MedTech landscape.
Read more →QTEXInspira Technologies Reports Full Year 2025
Inspira Technologies reported its financial results for the full year 2025, highlighting significant advancements in commercial execution for its INSPIRA ART100 system. The company achieved vendor approval to enter procurement pathways and made strides in discussions with various medical systems. Despite a net loss increasing to $13.2 million, Inspira managed to secure $4.75 million through a registered direct offering, which will strengthen its liquidity and strategic operations for 2026. The company continues to expand its clinical deployment and is focusing on converting growing opportunities into revenue.
Read more →QTEXReceives Nasdaq Notification Regarding Minimum Market Value Deficiency
Inspira Technologies has received a notification from Nasdaq regarding its non-compliance with the minimum market value requirement of $35 million. The company has until August 18, 2026, to regain compliance by maintaining the required market value for a minimum of 10 consecutive business days. While currently trading under the symbol 'IINN', the potential for delisting poses a significant risk if compliance is not achieved.
Read more →QTEXInspira Expands U.S.
Inspira Technologies has announced the deployment of its ART100 system at a new leading academic medical center in New York, which is ranked among the top 10 hospitals in the state. This deployment is part of a structured evaluation aimed at defining clinical protocols and assessing broader adoption. The initiative highlights Inspira's strategy to expand its commercial footprint within the U.S. healthcare sector, building on previous FDA clearances and successful evaluations at major health facilities.
Read more →QTEXInspira Technologies Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Requirement RA'ANANA, Israel
Inspira Technologies has received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement due to its shares trading below $1.00. The company has been given a compliance period of 180 days, until August 10, 2026, to meet this requirement. If compliance is not achieved, Inspira could be subject to a second compliance period but may ultimately face delisting. The company plans to monitor its share price and is exploring options to remedy the situation.
Read more →QTEXInspira Secures Vendor Approval from $12 Billion Revenue HMO (World's 2 nd Largest), Enabling Immediate ART100 Deployment RA'ANANA, Israel
Inspira Technologies has received vendor approval from Clalit Health Services, the second-largest HMO globally, for its ART100 system. This approval allows for immediate deployment of the technology across Clalit’s network. CEO Dagi Ben-Noon emphasizes that this milestone marks a significant commercial advancement, potentially leading to long-term revenue opportunities. The ART100 system is specially designed for use in cardiopulmonary procedures and is expected to enhance Inspira's positioning in the medical device market.
Read more →QTEXInspira Announces Pricing of $4.75 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules RA'ANANA, Israel
Inspira Technologies OXY B.H.N. Ltd. announced a definitive agreement for a registered direct offering of $4.75 million, intending to use the funds for working capital and general corporate purposes. The offering comprises 6,785,715 ordinary shares priced at $0.70 each and includes a concurrent private placement of unregistered warrants for the same number of shares with the same exercise price. A.G.P./Alliance Global Partners is the sole placement agent for this transaction, which is expected to close around February 6, 2026, pending the satisfaction of customary closing conditions.
Read more →QTEXInspira Technologies Validates Next-Gen Standalone HYLA Blood Sensor with Clinical-Grade Accuracy, Targeting $48 Billion Heart-Lung Surgery Market Company's validation confirms 94.2% accuracy for blood pCO measurement, p
Inspira Technologies has successfully validated its Next-Generation Standalone HYLA Blood Sensor, demonstrating a clinical-grade accuracy of 94.2% for measuring partial pressure of carbon dioxide (pCO). This innovation opens an immediate pathway for the company to penetrate the $50 billion heart-lung surgery market. The sensor’s standalone functionality allows it to integrate into existing workflows in operating rooms and ICUs. Moreover, the technology is expected to enhance patient monitoring by providing continuous, non-invasive visibility into metabolic status, thereby potentially reducing complications during procedures.
Read more →QTEXART100 Becomes Inspira's First System to Complete Clinical Evaluation and Enters Budgeted Procurement at Top U.S. Medical Center RA'ANANA, Israel
Inspira Technologies announced that its ART100 system has completed its clinical evaluation and entered a budgeted procurement phase at a top U.S. academic medical center. This marks the first time the ART100 has transitioned from pilot use to routine clinical workflow in such an institution, following successful treatment of approximately 30 patients. CEO Dagi Ben-Noon emphasized the milestone as validation of the technology's clinical value. The procurement process, though budget-dependent, is viewed as a significant step for broader adoption of the ART100 platform across healthcare institutions.
Read more →QTEXInspira Advances to Final Governmental Budgetary Validation Procedures for Previously Announced Binding Purchase Orders RA'ANANA, Israel
Inspira Technologies has made considerable strides in the execution of previously announced binding purchase orders, totaling $49.5 million. The company has reported that approximately 91% of these orders have successfully completed the necessary commercial and administrative reviews, now moving to the final budgetary validation stage. This step is crucial for future fund allocation and operational execution. The company is optimistic about revenue recognition related to these orders in the 2026 fiscal year, following the completion of governmental budgetary processes.
Read more →QTEXInspira Outlines Strategic Vision and Transaction Framework for Breast Cancer Liquid Biopsy Expansion Company details contemplated transaction structure designed to preserve shareholder value and enable future dividend d
Inspira Technologies has announced its strategic vision and a proposed transaction framework aimed at expanding into liquid biopsy diagnostics. The company plans to acquire an advanced liquid biopsy platform while simultaneously securing equity investments to support its ongoing operations and future dividend distributions. This expansion will build upon Inspira's existing strengths in blood diagnostics and real-time monitoring, particularly in the context of breast cancer diagnostics. The planned acquisition is structured to enhance shareholder value while positioning the company for long-term growth in the diagnostics sector.
Read more →QTEXInspira Signs Term Sheet for Acquisition of Advanced Liquid Biopsy Cancer Diagnostics Technology and Concurrent $15 Million Investment at $180 Million Valuation All-share acquisition positions Inspira to expand into a mu
Inspira Technologies has signed a term sheet for acquiring an advanced liquid biopsy diagnostics business and securing a concurrent $15 million investment, with a valuation of $180 million. The acquisition aims to enhance Inspira's offerings in the high-growth diagnostics sector, particularly targeting the liquid biopsy market, which is projected to reach $58 billion. The deal includes a dedicated framework to protect the interests of existing shareholders and ensures they benefit from future growth while providing access to a new diagnostics platform. Shareholder approval and customary conditions will follow the finalization of the definitive agreements in the coming weeks.
Read more →QTEXInspira Technologies Reaffirms $49.5 Million in Binding Purchase Orders and Aligns Execution with 2026 Regulatory and Deployment Milestones Revenues Relating to the Binding Purchase Orders Expected to be Received and Rec
Inspira Technologies has reaffirmed its binding purchase orders totaling $49.5 million, indicating strong expectations for payment activity to commence in the 2026 fiscal cycle. The company highlighted their alignment with immediate regulatory and deployment milestones while continuing to work closely with distribution partners and regulatory authorities. This proactive approach is designed to enhance operational visibility and reduce execution risk as they prepare for phased rollouts across target markets. Updates regarding execution and deployment milestones are anticipated in the future.
Read more →QTEXInspira Announces $1.8 Million Registered Direct Offering Priced At-The-Market and Additional Equity Financing Agreement to Support Ongoing Commercial Execution RA'ANANA, Israel
Inspira Technologies has announced a registered direct offering of 1,565,217 ordinary shares priced at $1.15 each, expected to generate approximately $1.8 million in gross proceeds. Additionally, the company has entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd. that allows for the sale of up to $25 million in ordinary shares over a 36-month period. The net proceeds will be used for working capital and to support the company's strategic initiatives and operations. This financing is aimed at strengthening the company's commercial execution and future growth potential.
Read more →QTEXInspira Technologies Granted Patent in Japan for the INSPIRA ART System's Convertible Dual Lumen Cannula Device and Method of Use RA'ANANA, Israel
Inspira Technologies has been granted a patent in Japan for its Convertible Dual Lumen Cannula device and its method of use. This patent, extending through 2041, provides exclusive commercial rights in a key medical device market and complements an existing U.S. patent. The innovative design of the cannula allows for conversion between lumen types intra-procedurally, which could enhance patient safety and reduce costs associated with traditional dual-lumen solutions. The company aims to leverage this patent to support future disposable product revenue streams and further expand its market presence.
Read more →QTEXInspira Technologies Announces Strategic Leap in Lab Capabilities - Accelerating Next-Generation Diagnostics and Blood Technology RA'ANANA, Israel
Inspira Technologies has announced a major expansion of its laboratory capabilities, which will enhance its capacity for next-generation diagnostics and blood technologies. The transition to a larger, state-of-the-art facility aims to support increased sample processing and integrate advanced capabilities into its operations. The company plans to recruit specialized personnel to strengthen its team and accelerate its technological development. This expansion aligns with Inspira's long-term strategy to solidify its position in the medical technology sector.
Read more →QTEXINSPIRA TECHNOLOGIES OXY B.H.N. Ltd. NOTICE OF ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that an Annual and Extraordinary General Meeting of Shareholders (the " Meeting ") of Inspira
Inspira Technologies Oxy B.H.N. Ltd. has called for its Annual and Extraordinary General Meeting to take place on December 30, 2025, at their office in Israel. Shareholders are invited to vote on several proposals including the re-election of board members and the approval of share units for a new director. The meeting will also include discussions on the audited financial statements for the year ending December 31, 2024.
Read more →QTEXInspira Completes Clinical Study for HYLA Blood Sensor - Ahead of Regulatory Submission RA'ANANA, Israel
Inspira Technologies has completed the clinical study for its HYLA non-invasive blood sensor, moving towards regulatory submission. The device demonstrated an accuracy of 95% to 99% in trial results, and the company is transitioning to the final validation and verification phases. HYLA aims to enhance patient monitoring and decision-making in critical care environments while addressing limitations of current non-invasive systems.
Read more →QTEXInspira Technologies Nears Final Regulatory Clearance for the ART100 in the UAE, Accelerating Gulf Region Expansion RA'ANANA, Israel
Inspira Technologies has completed the regulatory submission for its ART100 system to the UAE Ministry of Health and Prevention, expecting final approval imminently. This step is crucial for the company's expansion into the Gulf region's healthcare market. The UAE's innovation-driven regulatory framework supports this move, with the potential for widespread deployment following the anticipated authorization. The CEO highlighted their readiness to rapidly proceed with commercialization upon receiving approval.
Read more →QTEXInspira and Bites Form Strategic Alliance to Embed AI as a Core Standard Across Inspira's Global Ecosystem RA'ANANA, Israel
Inspira Technologies has formed a strategic alliance with Bites Learning to incorporate AI-based digital training and performance solutions within Inspira's ecosystem. This collaboration aims to standardize competencies and streamline onboarding processes for healthcare providers globally. The integration of Bites' AI technology is expected to enhance operational performance and accelerate the adoption of Inspira's medical devices. The partnership positions Inspira to redefine digital transformation in the medical device sector while potentially increasing shareholder value.
Read more →QTEXInspira Appoints Former Johnson & Johnson Senior Business Manager as VP of Global Sales and New Board Member from a Leading International Investment Firm RA'ANANA, Israel
Inspira Technologies has made two significant leadership appointments aimed at enhancing its global commercialization efforts. Mike Hershkovitz has been named Vice President of Global Sales, bringing nearly two decades of experience from companies like Johnson & Johnson. Sivan Matza joins the board as an independent director, bringing her substantial financial management experience from a leading investment firm. These additions are part of Inspira's strategy to strengthen its governance and accelerate the adoption of its innovative technologies in hospitals worldwide.
Read more →QTEXInspira Technologies Reports First Half 2025 Financial Results and Issues Business Update Inspira delivered major milestones throughout and following the six months ended
Inspira Technologies reported its financial results for the first half of 2025, showcasing significant achievements, including $49.5 million in binding purchase orders and clinical validation for its HYLA blood sensor. The company indicated a shift from development to commercial operations, highlighting a strong accuracy rate of 97.35% for its sensor technology. Despite these positive milestones, Inspira is currently facing operating losses and a considerable accumulated deficit, with revenues beginning to materialize. The management is optimistic about scaling production and anticipates substantial revenue growth in the coming years.
Read more →QTEXInspira to Unveil HYLA Real-Time Blood Sensor at U.S. ELSO; 97.35% Accuracy Confirmed RA'ANANA, Israel
Inspira Technologies will unveil its HYLA real-time blood sensor at the upcoming U.S. ELSO Annual Conference, showcasing its impressive accuracy of 97.35% compared to traditional blood gas analyzers. The event serves as a significant platform for Inspira to connect with key industry stakeholders and explore potential commercialization opportunities. Alongside the HYLA sensor, the company will present its FDA-cleared ART100 system, reaffirming its commitment to advancing life-support technologies. CEO Dagi Ben-Noon emphasized the strategic importance of this presentation for elevating clinical standards.
Read more →QTEXInspira Announces 97.3% Accuracy Results for HYLA Blood Sensor, Advancing Toward FDA Submission for Clearance RA'ANANA, Israel
Inspira Technologies announced a significant milestone with its HYLA Blood Sensor achieving an accuracy of 97.35% in recent performance testing. This achievement supports the company's preparations for FDA submission, positioning the device favorably for regulatory approval in both the U.S. and Europe. The HYLA Blood Sensor is designed for real-time monitoring of blood parameters, which is expected to greatly improve critical care by providing instant alerts to medical teams. Inspira also notes growing interest in this technology from major global medtech firms, highlighting its potential impact in the market.
Read more →QTEXTop U.S. Honor Roll Hospital Expands Use of INSPIRA ART100 System to Lung Transplant Procedures RA'ANANA, Israel
Inspira Technologies OXY B.H.N. Ltd. has announced that a leading U.S. hospital has expanded its use of the INSPIRA ART100 system to include lung transplantation procedures. This decision follows a positive experience with the ART100 in other clinical applications. The move is seen as strong validation of the system's performance and may pave the way for more widespread adoption in advanced respiratory care. Furthermore, this expansion reflects growing confidence in Inspira’s innovative technologies within the medical community.
Read more →QTEXInspira Receives U.S. Patent Approval for the ART500 Core Technology, Key Patent Positions the Company to Dominate $20 Billion Estimated Market RA'ANANA, Israel
Inspira Technologies has received U.S. Patent approval for its ART500 Core Technology, essential for advancing respiratory support systems. This patent, which contains 16 novel claims, positions Inspira to leverage a substantial estimated market worth $20 billion. The ART500’s design caters to a growing patient population requiring low-flow oxygenation solutions, potentially shifting standards of care. The company aims to enhance its intellectual property coverage further by pursuing additional patents worldwide.
Read more →QTEXInspira Secures $27 Million Government Binding Purchase Order for ART100 Systems with Full Payment in 2025 RA'ANANA, Israel
Inspira Technologies has announced a $27 million binding purchase order for its ART100 systems from a national ministry of health in Africa, with full payment expected in 2025. This order is a significant validation of Inspira's commercial model and contributes to a total of $49.5 million in orders secured for 2025. The partnership emphasizes the importance of the ART100 systems in enhancing national emergency and critical care infrastructure. Shipments and installations are scheduled to begin in coordination with the ministry, marking the start of a nationwide deployment program.
Read more →QTEXInspira Activates U.S. Based Consulting Firm to Execute Transformational Initiatives RA'ANANA, Israel
Inspira Technologies has activated a leading U.S.-based consulting firm to support its strategic expansion and enhance commercial growth. The firm's specialized expertise is expected to facilitate high-impact execution and transform the company's market position. Notable achievements noted by CEO Dagi Ben-Noon include major purchase orders and clinical integration of its ART100 system in U.S. hospitals. The collaboration aims to catalyze new value creation initiatives in the latter half of 2025.
Read more →QTEXInspira Regains Compliance with Nasdaq Minimum Bid Price Requirement RA'ANANA, Israel
Inspira Technologies has announced that it has regained compliance with Nasdaq's minimum bid price requirement, following a sustained increase in its share price. This milestone reflects the company's progress and growing market confidence in its business strategy. Recent achievements, including a significant commercial order and advancements in government partnerships, signal a transformative shift for Inspira. The company is now focused on expanding global distribution and enhancing long-term shareholder value.
Read more →QTEXInspira Achieves All Key Objectives in Previously Announced Government Talks, Forging a Pathway to National Adoption and Global Scale-Up of the ART100 RA'ANANA, Israel
Inspira Technologies has successfully completed key objectives in talks with a government health authority regarding the ART100 system. This meeting has established a framework for national adoption and future global scale-up of the ART100, recognized for its clinical validation. The company's CEO highlighted the achievement as a catalyst for transforming Inspira into a commercially-focused entity. The integration aims to enhance the company's existing purchase order and establish a distribution hub for global operations.
Read more →QTEXInspira in High-Level Government Talks to Advance National Integration of the ART100 and Establish a Global Distribution Framework RA'ANANA, Israel
Inspira Technologies is in discussions with a government health authority to integrate its ART100 system into national emergency infrastructure. The meeting, which aims to define the terms for collaboration, showcases Inspira's shift towards global partnerships beyond regional deals. This development follows a significant purchase order worth $22.5 million that highlights the government's commitment to next-generation medical technologies. The outcome of these talks could position Inspira favorably in the global health market and maximize the profitability of its recent contracts.
Read more →QTEXInspira Technologies Secures $22.5 Million Purchase Order, Launches Full Revenue Execution Phase RA'ANANA, Israel
Inspira Technologies announced a binding $22.5 million purchase order for its FDA-cleared ART100 system, signaling a pivotal shift towards revenue generation. The order was placed by a private company with an established reputation, paving the way for immediate implementation and logistics planning. This milestone supports Inspira's expansion strategy as it continues negotiations with additional healthcare partners. The agreement underscores the demand for the ART100 technology in real-world clinical settings.
Read more →QTEXInspira's ART100 in Use at Tier-1 U.S. Hospitals, Generating Strong Clinical Interest and Accelerating Sales Discussions RA'ANANA, Israel
Inspira Technologies announced that its ART100 system has begun successful use in tier-one U.S. hospitals, leading to increased clinical interest and accelerating sales discussions. This adoption is seen as a key milestone for the company, indicating growing confidence in the system’s ability to support critically ill patients. The company is currently scaling up operational capabilities in response to heightened interest from additional healthcare institutions and government authorities. Executives emphasize this integration into clinical workflows as a significant step toward commercial validation and future growth.
Read more →QTEXInspira Scales Up ART100 Production Capabilities Amid Advanced Negotiation with European Government Authority RA'ANANA, Israel
Inspira Technologies announced an increase in production capabilities for its FDA-cleared ART100 system to meet anticipated demand from a European government authority. The company is currently engaged in advanced procurement negotiations aimed at finalizing a deal. The ART100, already used in U.S. clinical settings, is positioned as a crucial device for critical care and emergency preparedness. Inspira's efforts are part of a larger global rollout strategy, reflecting their commitment to enhance revenue generation and address public health needs.
Read more →QTEXINSPIRA TECHNOLOGIES OXY B.H.N. Ltd. NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that an Extraordinary General Meeting of Shareholders (the " Meeting ") of Inspira Technologies Oxy B.H.
Inspira Technologies Oxy B.H.N. Ltd. has scheduled an Extraordinary General Meeting on June 20, 2025, primarily to discuss a proposed reverse split of its ordinary shares by a ratio of 2:1 to 25:1. This measure is intended to address compliance issues with Nasdaq's minimum bid price requirements, following a notice received from Nasdaq due to the Company’s stock falling below $1.00. The Board of Directors has unanimously recommended that shareholders vote in favor of this proposal.
Read more →QTEXInspira Technologies Initiates Global Commercial Rollout of FDA-Cleared ART100 System Following successful clinical implementations in the U.S., Inspira accelerates commercialization of its system. The Company is already
Inspira Technologies has initiated a global commercial rollout of its FDA-cleared ART100 system following successful clinical implementations in the U.S. The company is currently engaged in discussions with governmental health departments and private organizations to further accelerate commercialization. With deliveries expected in the second half of 2025, Inspira aims to leverage the rising demand for alternative respiratory solutions while advancing its innovation pipeline.
Read more →QTEXInspira Technologies Aligns Executive Team Amid Corporate Structuring Initiatives RA'ANANA, Israel
Inspira Technologies has announced a restructuring of its executive team as part of its long-term strategic alignment efforts. Co-Founder and President Joe Hayon is stepping down from his operational role but will continue as an active Board member. This decision is aimed at streamlining leadership and enhancing operational clarity without impacting ongoing operations or research timelines. The company's strategic realignment reflects its commitment to advancing in the rapidly changing healthcare landscape.
Read more →QTEXINSPIRA ART100 System Approved by Israel's Largest Healthcare Provider for Use in Organ Transplant Patients RA'ANANA, Israel
Inspira Technologies has announced that its INSPIRA ART100 system has received approval from Israel's largest healthcare provider for use in organ transplant patients. The system will undergo clinical validation at a renowned medical center, where physicians aim to evaluate its effectiveness in maintaining organ viability during transplant procedures. This development represents a significant opportunity for the company to gather clinical data that could enhance the ongoing development of its flagship INSPIRA ART500 system. The approval underscores the growing interest in Inspira's innovative technologies within the medical community.
Read more →QTEXInspira Achieves above 99% Gas Exchange Efficiency in VORTX Technology In Vivo Animal Testing RA'ANANA, Israel
Inspira Technologies announced a significant breakthrough in its VORTX technology, achieving over 99% gas exchange efficiency during in-vivo testing. This advancement has the potential to significantly improve respiratory care by providing a less invasive alternative to traditional mechanical ventilation methods. The in-vivo tests were conducted on swine at a leading research facility and validated previous laboratory findings. Moving forward, Inspira plans to refine this technology and expects to release further updates soon.
Read more →QTEXInspira Technologies Generates First Revenues from Deployment of INSPIRA ART100 Systems The Company achieves significant milestone with initial revenues generated from FDA-cleared life support technology deployed in a le
Inspira Technologies has successfully generated its first revenues from the FDA-cleared INSPIRA ART100 life support systems, installed at a premier U.S. healthcare facility. This achievement marks a significant milestone in the company's deployment strategy, showcasing its innovative technology. The company plans to expand its footprint further by deploying additional systems at a second academic medical center. CEO Dagi Ben-Noon emphasized that this development validates the company's capabilities and paves the way for future growth in the U.S. market.
Read more →QTEXInspira Technologies Announces Successful Treatment of First Patient with INSPIRA ART100 at Westchester Medical Center First Clinical Use of INSPIRA ART100 System Successfully Completes Full Treatment Cycle, Validating t
Inspira Technologies announced the successful treatment of its first patient using the INSPIRA ART100 system at Westchester Medical Center. This marks the system's first clinical implementation, effectively providing heart and lung support. Physicians reported high reliability and responsiveness of the system during the procedure, which successfully transitioned the patient off the technology. The positive outcome is expected to facilitate broader adoption of the technology in other hospitals.
Read more →QTEXInspira Technologies Announces Successful Installation of INSPIRA ART100 Systems in Premier U.S. Hospital Inspira's innovative FDA-cleared INSPIRA ART100 system was successfully deployed at premier U.S. hospital, with sy
Inspira Technologies has successfully installed its FDA-cleared INSPIRA ART100 system in a premier U.S. hospital, marking a significant milestone in its deployment plan. The company has completed training and operational readiness, which paves the way for clinical use in cardiopulmonary bypass procedures. This installation is expected to validate the clinical value of Inspira's technology and enhance its commercial presence in the U.S. healthcare market. The INSPIRA ART500, the company's flagship technology, aims to revolutionize the mechanical ventilation industry by providing a safer, human-centered alternative.
Read more →QTEXInspira Technologies Releases CEO Update: Major Milestones Signal Next-Level Respiratory Care Letter from the CEO /
Inspira Technologies has shared an update highlighting major advancements in its respiratory support technology, specifically the INSPIRA ART500 system. This next-generation device aims to improve oxygen levels in patients with Acute Respiratory Failure without invasive mechanical ventilation. The company is targeting a significant portion of the $19 billion U.S. mechanical ventilation market and is preparing for an FDA submission within the next 18 months. CEO Dagi Ben Noon emphasized the device's potential to transform critical care and enhance patient dignity while reducing complications associated with traditional ventilation methods.
Read more →QTEXInspira Technologies Receives Nasdaq Notification Regarding Minimum Bid Requirement Ra'anana, Israel
Inspira Technologies OXY B.H.N. Ltd. received a notification from Nasdaq indicating non-compliance with the minimum bid price requirement, as its ordinary shares have closed below $1.00 for the last 30 days. The Company has until September 8, 2025, to regain compliance or may face delisting. If necessary, it can apply for a second compliance period, provided it meets other listing standards. Inspira plans to monitor its share price and explore options to address this deficiency while continuing to trade on Nasdaq.
Read more →QTEXInspira Technologies Reports Full Year 2024 Financial Results and Provides Business Updates Significant progress in HYLA blood sensor and INSPIRA ART core technologies RA'ANANA, Israel
Inspira Technologies has reported its financial results for 2024, highlighting significant advancements in its core technologies, including the INSPIRA ART100 system, which has received FDA clearance. The company is preparing for deployment of this system in U.S. hospitals while also advancing its HYLA blood monitoring sensor for an anticipated FDA submission later in 2025. Despite progress, Inspira faced financial challenges, including an overall loss for the year and a growing accumulated deficit.
Read more →QTEXInspira Technologies Announces Positive Results from Clinical Study of HYLA Blood Sensor, Achieving 96% Accuracy Inspira's AI-powered continuous blood monitoring technology demonstrated a high degree of accuracy in a key
Inspira Technologies has announced promising results from its clinical study of the HYLA Blood Sensor, which demonstrated a high accuracy of 96%. This AI-powered device allows for continuous blood monitoring without the need for traditional blood draws. Conducted at Sheba Hospital, the study involved monitoring patients undergoing open-heart surgery. Following these results, Inspira plans to advance its clinical studies and submit an application for FDA approval by the second half of 2025.
Read more →QTEXInspira Achieves Positive Results of Above 95% For Preventing Bloodstream Infections The ex-vivo testing demonstrated significant bacterial reduction for the innovative IV dressing technology aimed at preventing bloodstr
Inspira Technologies announced that its novel bio-electronic patch achieved a 95% reduction in bacterial presence during ex-vivo testing on porcine skin models. This technology, developed in collaboration with Ennocure MedTech, aims to prevent bloodstream infections in critical care settings. The patch uses physical electric stimulation instead of chemical agents, showing promise for infection prevention. With an estimated 250,000 bloodstream infections related to intravenous lines worldwide annually, the breakthrough technology could significantly improve patient care.
Read more →QTEXInspira Technologies Integrates New Oxygenation Indicator into AI-Powered HYLA Blood Sensor Inspira Technologies develops its innovative AI-powered HYLA technology with advanced blood testing capability, enabling continu
Inspira Technologies has announced the integration of a new oxygenation indicator into its AI-powered HYLA blood sensor, aimed at improving the monitoring of tissue oxygenation and early hypoxia detection. The new technology enables continuous, real-time monitoring without the need for intermittent blood draws. Currently, clinical validation is being conducted at Sheba Medical Center, with preliminary results expected soon. The company is optimistic about the ongoing evaluations and anticipates submitting for FDA regulatory clearance in the latter half of 2025.
Read more →QTEXInspira Introduces Advanced Features for INSPIRA ART100, Further Amplifying User and System Support Ra'anana, Israel
Inspira Technologies announced advanced features for their INSPIRA ART100 system, aimed at improving support for medical teams during critical procedures. These enhancements are designed to integrate seamlessly with existing hospital protocols, thereby mitigating staff overhead and optimizing efficiency. The updated system offers valuable resources such as system-activated alarm troubleshooting and an accessible interface for use in challenging care situations. With these developments, Inspira continues to position itself as a leader in life support technology.
Read more →QTEXInspira Announces the Appointment of Tal Parnes as the New Chairman of the Board, Bringing Vast Experience in the Medical Technology and Pharmaceutical Sectors Ra'anana, Israel
Inspira Technologies has appointed Tal Parnes as the new chairman of the board of directors, effective February. Parnes has extensive experience in the medical technology and pharmaceutical sectors, having served as an independent director since 2021. His leadership is anticipated to refine the company's strategic vision and enhance its competitive position in the market. The company also expresses gratitude to the outgoing chairman, Prof. Benad Goldwasser, for his contributions prior to stepping down for personal reasons.
Read more →QTEXInspira Technologies Collaborates With Zriha Medical To Launch Cutting-Edge Production Line Ra'anana, Israel
Inspira Technologies has partnered with Zriha Medical to establish a dedicated production line for a critical component of its respiratory support system. This collaboration aims to enhance the production of Inspira's devices, potentially expediting their market entry. Zriha Medical's expertise in clean room manufacturing will facilitate the integration of a flow mechanism into Inspira's products, which are designed for blood oxygenation processes. The new production capabilities are expected to support Inspira's innovative approaches in respiratory treatment technologies.
Read more →QTEXInspira Technologies Unveils Modular Configuration for Revolutionary VORTX Blood Oxygenation Delivery Technology The technology has the potential to provide life-saving support for the approximately 20 million ICU patien
Inspira Technologies OXY B.H.N. Ltd. has announced the development of a modular configuration for its VORTX blood oxygenation delivery technology. This innovative system aims to provide essential support for approximately 20 million ICU patients with respiratory failure each year, potentially transforming critical care practices. The VORTX technology distinguishes itself from traditional systems by maintaining more natural blood flow, which may reduce harmful effects on blood components. With 32 patent claims, Inspira's technology is poised to make significant advancements in respiratory care and patient outcomes.
Read more →QTEXInspira Preparing Production in Response to Spread of Respiratory Virus in China Ra'anana, Israel
Inspira Technologies is preparing to ramp up production of its INSPIRA ART100 device due to a recent outbreak of human metapneumovirus (hMPV) in China. The company is assessing demand with healthcare providers in affected regions and is ensuring sourcing of necessary materials for production. Inspira's CEO emphasizes the precautionary nature of these measures while also highlighting the device's readiness to meet potential increases in demand for advanced respiratory care.
Read more →QTEXInspira Technologies Flagship Technology to be Showcased at Arab Health Expo 2025 in Dubai Visitors at Glo-Med Network Inc's booth can explore Inspira's cutting-edge respiratory solutions, with the FDA-cleared INSPIRA AR
Inspira Technologies Oxy B.H.N. Ltd. is set to showcase its INSPIRA ART100 system at the Arab Health Expo 2025 in Dubai. This FDA-cleared cardiopulmonary bypass system offers unique respiratory support features, aimed at improving patient outcomes. The event, scheduled from January 27 to January 30, 2025, is expected to attract healthcare professionals and companies from across the globe, facilitating potential market expansion and partnerships for Inspira Technologies.
Read more →QTEXSECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this " Agreement ") is dated as of
Inspira Technologies OXY B.H.N. Ltd. has established a Securities Purchase Agreement dated December 27, 2024, with various purchasers. The document outlines the terms and conditions under which the company will issue securities, adhering to relevant SEC regulations. The Agreement elaborates on specific terms and the legal framework surrounding these securities transactions, including definitions and procedural guidelines that must be followed by both the company and the purchasers.
Read more →QTEXInspira Technologies Delivers Systems to Leading Distributor for U.S. Deployment RA'ANANA, Israel
Inspira Technologies has successfully delivered its INSPIRA ART100 systems to Glo-Med Networks Inc, a U.S. distributor, to enhance cardiopulmonary care in leading hospitals. The deployment is part of the company's strategy to introduce innovative respiratory support technology to U.S. healthcare providers. The INSPIRA ART100, which has FDA clearance for cardiopulmonary bypass procedures, is set to be integrated with the HYLA blood monitoring system to improve patient monitoring. The systems are intended for use in high-ranking hospitals, supporting the company's goal of revolutionizing respiratory care.
Read more →QTEXInspira Expands HYLA Blood Sensor Technology into Personalized Blood Lab Testing for Rapid Detection of Serious Medical Conditions RA'ANANA, Israel
Inspira Technologies has announced the expansion of its HYLA blood sensor technology into personalized blood lab testing for the rapid detection of serious medical conditions. This innovative approach aims to facilitate real-time blood work at the bedside, significantly improving efficiency and reducing the reliance on traditional blood sampling methods. The HYLA technology is currently undergoing clinical evaluations at Sheba Hospital, with plans for an FDA submission in 2025. The development aligns with Inspira's broader strategy to revolutionize patient care through advanced technology in life support and respiratory treatment.
Read more →QTEXInspira Collaborates with New York's Westchester Medical Center to Evaluate the INSPIRA ART100 Functionality and Performance in Clinical Scenarios Ra'anana, Israel
Inspira Technologies has entered a strategic collaboration with Westchester Medical Center to assess the functionality of its FDA-cleared INSPIRA ART100 systems in clinical scenarios. This partnership is aimed at enhancing patient care for those suffering from acute respiratory failure. The collaboration reflects the company's commitment to innovative technology in healthcare and may pave the way for further development of its next-generation INSPIRA ART system. Insights gained from this collaboration are expected to provide valuable data on the performance of the technology in real-world settings.
Read more →QTEXINSPIRA TECHNOLOGIES OXY B.H.N. Ltd. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that an Annual General Meeting of Shareholders (the " Meeting ") of Inspira Technologies Oxy B.H.N. Ltd. (" Ins
Inspira Technologies Oxy B.H.N. Ltd. has announced its Annual General Meeting (AGM) scheduled for December 30, 2024, at 4:00 p.m. Israel time. The meeting will discuss the audited consolidated financial statements for the fiscal year ending December 31, 2023, alongside other business proposals. Shareholders of record as of December 2, 2024, are granted the right to attend the meeting in person or by proxy. The Board of Directors proposes to vote in favor of the presented proposals, with instructions provided for those unable to attend.
Read more →QTEXSee Disclaimers on slides 1 - 16 . Copyright 2018 - 2024 Inspira Technologies OXY B.H.N. LTD., All rights reserved 1 See Disclaimers in deck on slides 3 Copyright 2018 - 2024 Inspira Technologies OXY B.H.N. LTD., All rig
Inspira Technologies is navigating the complexities of regulatory approvals for its medical devices, including the INSPIRA ART 100 system, which is FDA cleared for certain uses. However, many of its other products, including the INSPIRA ART and HYLA technologies, remain in development and have not yet undergone human testing. The timelines for these products' approvals are subject to significant variability and uncertainty, highlighting potential risks for the company. Additionally, the presentation emphasizes the need for further validation and study parameters for future regulatory submissions.
Read more →QTEXInspira Announces Establishment of Distribution Facility to Support U.S. Deployment of INSPIRA ART100 The Company has signed a distribution agreement that assigns to Glo-Med the role of Inspira's primary distributor and
Inspira Technologies has established a distribution agreement with Glo-Med Networks to support the U.S. deployment of its INSPIRA ART100 device, which is designed for cardiopulmonary bypass procedures. The agreement includes a new distribution facility located in Florida that will serve as a hub for distribution and customer support. The INSPIRA ART100 is FDA-cleared and aims to improve life support for patients with acute respiratory failure. This strategic move is expected to boost Inspira's market presence and operational capabilities while also preparing for future product launches.
Read more →QTEXInspira Announces Development of New Disposable Kit with Built-In Performance Monitoring Mechanism Ra'anana, Israel
Inspira Technologies has revealed the development of a new disposable kit aimed at the perfusion market, which aligns with the company's strategy to generate recurring revenue. This kit features built-in performance monitoring to enhance patient safety and improve the experience for medical teams. Following FDA clearance for its INSPIRA ART100 system, the disposable kit is scheduled to enter the market, potentially tapping into a significant $1 billion opportunity within the perfusion systems market. The initial deployment of these kits in the U.S. is anticipated by the end of 2024.
Read more →QTEXInspira Secures a Second U.S. Patent Approval for Orbiting Blood Oxygenation Delivery System To date, a combined total of 32 claims have been deemed novel for the core technology of the INSPIRA ART device Targeting treat
Inspira Technologies has received a second U.S. patent approval for its VORTX orbiting blood oxygenation delivery system, increasing the total number of novel claims for its INSPIRA ART device to 32. This technology aims to improve care for 20 million ICU patients affected by respiratory failure each year by maintaining stable oxygen levels and potentially reducing reliance on mechanical ventilators. The system’s design seeks to minimize blood damage typically associated with existing fiber oxygenation methods. The company is poised to make significant advancements in the $19 billion mechanical ventilation market.
Read more →QTEXInspira to Publish HYLA Clinical Results in Fourth Quarter 2024 The clip-on HYLA blood sensor, designed to alert physicians of immediate signs of changes in a patient's clinical condition without the need for intermitten
Inspira Technologies announced plans to publish clinical results for its HYLA blood sensor in the fourth quarter of 2024. This device is designed for continuous monitoring of patients without the need for intermittent blood samples, aiming to provide immediate alerts about clinical condition changes. The company seeks FDA approval for integration with its existing INSPIRA ART100 systems, with plans for a potential standalone version as well. This development is part of Inspira's strategy to enhance its product offerings in the life-support technology sector.
Read more →QTEXInspira Technologies Announces FDA Listing and Market Readiness of New Product Ra'anana, Israel
Inspira Technologies announced the FDA listing and market readiness of its INSPIRA CART, a medical cart designed for use with the INSPIRA ART100 system during cardiopulmonary bypass procedures. This approval as a Class I Medical Device highlights the product's compliance with safety and efficacy standards. The company reports receiving its first orders for the INSPIRA CART, reflecting positive market reception. Additionally, Inspira Technologies is advancing a pipeline of innovative life-support technologies targeting a substantial market opportunity.
Read more →QTEXINSPIRA TECHNOLOGIES OXY B.H.N. LTD. INTERIM CONDENSED FINANCIAL STATEMENTS AS OF JUNE 30, 2024 UNAUDITED _______________________ ________________ ____________ INSPIRA TECHNOLOGIES OXY B.H.N. LTD. (UNAUDITED) TABLE OF CO
Inspira Technologies OXY B.H.N. Ltd. has released its interim condensed financial statements for the six months ending June 30, 2024. The company's total assets rose slightly to $9,422,000, with current assets totaling $8,084,000. However, the interim reports indicate an operating loss and an increase in accumulated losses, reflecting continued financial challenges. The report also highlights the development of several medical devices aimed at enhancing patient care through innovative respiratory support technology.
Read more →QTEXInspira Approached by Large Medical Company to Evaluate Operation of their Key Product with INSPIRA ART100 - Results Exceed 100% at Maximum Flow Ra'anana, Israel
Inspira Technologies has announced a successful evaluation of its INSPIRA ART100 system in collaboration with a leading medical technology company. The evaluation demonstrated that the product exceeded 100% of standard gas transfer values at maximum flow, meeting specified requirements without technical malfunctions. This positive outcome reflects the advanced capabilities of the INSPIRA ART100 system and may support the company in developing further business opportunities within the medical device industry.
Read more →QTEXInspira Technologies Introduces the INSPIRA Cardi-ART, Aiming to Provide Oxygen to the Brain During Cardiac Arrest Inspira's innovation targets life-saving intervention for patients with cardiac arrest, of which there ar
Inspira Technologies has unveiled the INSPIRA Cardi-ART, a portable device aimed at delivering oxygen to the brain during cardiac arrest. This innovation targets a significant gap in emergency medical care, particularly as nearly 70% of cardiac arrests occur outside of hospitals. The company plans to submit the device for FDA approval by 2026 while highlighting its potential to enhance survival rates in cardiac arrest scenarios. The launch captures a vital market opportunity valued at approximately $58.8 billion, combining the cardiac arrest and mechanical ventilation markets.
Read more →QTEXInspira Receives Israeli Regulatory Approval for the INSPIRA ART100 System Approval follows the FDA clearance announced on
Inspira Technologies OXY B.H.N. Ltd. has received regulatory approval from the Israeli Ministry of Health for its INSPIRA ART100 system, an important development following recent FDA clearance. This approval is seen as a significant milestone that could enhance local support and market adoption of the device. Dagi Ben-Noon, the CEO, emphasized the approval's potential to create business opportunities in new and emerging markets. The INSPIRA ART100 is designed to provide life support effectively while elevating patient comfort by potentially reducing the need for mechanical ventilation.
Read more →QTEXInspira Announces Business Plan Targets Company to aggressively promote INSPIRA ART100 in the U.S. and additional markets following FDA clearance, as well as accelerate plans for ground-breaking INSPIRA ART (Gen2) Ra'ana
Inspira Technologies OXY B.H.N. Ltd. has announced an aggressive business plan to promote its FDA-cleared INSPIRA ART100 and accelerate the development of the groundbreaking INSPIRA ART (Gen 2) device. The company aims to capture a share of the $19 billion mechanical ventilation market with technology designed for direct blood oxygenation, potentially allowing awake patients to avoid intubation. The first purchase order from a U.S. distributor signals market momentum, although other products await regulatory approval. The company's future depends on successful deployment and further FDA clearances.
Read more →QTEXInspira Receives First Ever Purchase Order for INSPIRA ART100 Systems in U.S. First units expected to be shipped in Q4 2024. The Purchase Order follows the recent FDA Clearance of the INSPIRA ART100. Ra'anana, Israel
Inspira Technologies OXY B.H.N. Ltd. announced it has received its first purchase order for INSPIRA ART100 systems from Glo-Med Networks, Inc., with the initial five units expected to ship in Q4 2024. This order follows the recent FDA clearance for the system. The company is preparing to target the $19 billion mechanical ventilator market with future developments, namely the INSPIRA ART (Gen 2). The order also includes provisions for the potential purchase of an additional 20 systems, enhancing the company’s growth prospects.
Read more →QTEXINSPIRA ART100 Receives FDA 510(k) Clearance Ra'anana, Israel
Inspira Technologies OXY B.H.N. Ltd. has announced that it received FDA 510(k) clearance for its INSPIRA ART100 Cardiopulmonary Bypass System. The CEO and Chairman expressed pride in this milestone, indicating it reflects the company's innovative capabilities. The system is designed to improve patient oxygen saturation levels quickly and may allow patients to remain awake during treatment, enhancing care in intensive settings. Other products from the company remain unapproved and untested on humans.
Read more →QTEXInspira Announces Start of Production of the INSPIRA ART100 Ra'anana, Israel
Inspira Technologies has announced the commencement of production for its INSPIRA ART100 medical device in Ra'anana, Israel. This device is aimed at enhancing respiratory treatment and is being contract manufactured by a specialized technology company. While the production is underway, the devices will not be deployed until they receive FDA regulatory clearance. Additionally, the INSPIRA ART100 has not yet been tested in humans or approved by any regulatory body.
Read more →QTEXInspira Receives CSA Certification of Compliance to U.S. Standards for the INSPIRA ART100 Ra'anana, Israel
Inspira Technologies has announced that its INSPIRA ART100 device has received CSA Certification of Compliance to U.S. standards, representing an important milestone for the company. This certification enables the device to carry the CSA Mark, reflecting compliance with rigorous safety and performance requirements. Despite this achievement, the INSPIRA ART100 is still pending FDA regulatory clearance and has not yet been tested in humans, underscoring the need for further validation before market access. Moreover, the company is aware of various uncertainties that could impact future results.
Read more →QTEXInspira Signs Term Sheet for Use of INSPIRA ART100 Device in Organ Transplant Procedures Ra'anana, Israel
Inspira Technologies OXY B.H.N. Ltd. has entered into a collaboration term sheet with Beilinson Hospital in Israel to evaluate its INSPIRA ART100 device for use in organ transplant procedures. This development is seen as a significant opportunity for Inspira to expand its technology into new medical segments. The collaboration aims to gather data and feedback from medical professionals to assess the device's functionality in clinical settings. However, the agreement remains contingent on regulatory clearance from the Israeli Ministry of Health.
Read more →QTEXInspira and Ennocure In Vitro Study Results Show 100% Prevention of Bacterial Growth that Causes Bloodstream Infections Ra'anana, Israel
Inspira Technologies and Ennocure MedTech announced positive results from their in vitro study, demonstrating a 100% prevention of bacterial growth associated with bloodstream infections. The study, conducted at the Hebrew University of Jerusalem, showcased a bio-electronic treatment that significantly reduces bacterial proliferation. The companies plan to advance their collaboration towards future human trials, indicating a commitment to address infection prevention in intensive care settings. This innovative technology aims to enhance patient treatment while minimizing reliance on traditional antiseptic methods.
Read more →QTEXInspira Announces Program to Pioneer the Applicable Use of the INSPIRA ART100 Device for an Artificial Womb Ra'anana, Israel
Inspira Technologies has launched a program to explore the application of their INSPIRA ART100 device for use as an artificial womb to provide vital respiratory support to neonates. This potential advancement aims to replace mechanical ventilators, which can lead to long-term complications in at-risk infants. The initiative could significantly benefit prematurely born neonates and those suffering from critical respiratory disorders. However, the device is not yet tested on humans and has not received regulatory approval.
Read more →QTEXInspira Announces $1.65 Million Registered Direct Offering of Ordinary Shares by Inspira CEO's Mother with Leading Fund Manager Ra'anana, Israel
Inspira Technologies announced a registered direct offering of ordinary shares amounting to $1.65 million, facilitated by a leading fund manager in Israel and involving its CEO's mother. The offering includes 1,339,285 shares priced at $1.232 each and is expected to close by April 2, 2024. The proceeds will be utilized for working capital and general corporate purposes. This strategic move aims to bolster the company's financial position while advancing its healthcare technology innovations.
Read more →QTEXInspira Technologies Reports Full Year 2023 Financial Results FDA Submission for approval of INSPIRA ART100 95% Accuracy Results for HYLA Blood Sensor Compared to Standard Blood Gas Analyzers Granted U.S. Patent for INSP
Inspira Technologies announced positive advancements in its financial and technological developments for 2023. The company reported a significant achievement with its HYLA blood sensor achieving 95% accuracy, and an FDA submission for their INSPIRA ART100 device is underway. Despite a decrease in operating expenses, cash reserves have also declined significantly. Inspira Technologies is actively pursuing strategic partnerships to leverage market opportunities and accelerate the approval processes for their innovative medical devices.
Read more →QTEXInspira Announces AMAR Regulatory Submission of the INSPIRA ART100, to Enter the Southeast Asia and South American Markets Ra'anana, Israel
Inspira Technologies has announced the AMAR regulatory submission for its INSPIRA ART100 device, aiming to enter the Southeast Asian and South American markets. This submission marks a critical progression in Inspira's development of advanced blood oxygenation technology, designed to reduce reliance on mechanical ventilation. The company's CEO expressed pride in this milestone, citing the enthusiastic support from local key-opinion leaders. However, it is important to note that the device has yet to be tested or approved, leaving inherent risks associated with the commercialization process.
Read more →QTEXInspira Releases New Data Demonstrating Superiority of its Core Technology, Across Key Endpoints of HMSS Indicator An unprecedented achievement of a zero pressure gradient measured when using the VORTX device, directly c
Inspira Technologies announced the successful performance of its VORTX device, achieving zero pressure gradient during blood oxygenation and carbon dioxide removal. This marks a significant advancement in medical technology aimed at reducing complications associated with traditional mechanical ventilators. The device monitors essential metrics while minimizing shear stress that can harm blood components. The company believes this breakthrough could transform the approach to patient respiratory care, moving away from conventional membrane-based devices.
Read more →QTEXInspira Announces Plans to Report the Primary Results for a Core Blood Oxygenation Technology Within Days The major milestone refers to Inspira's proprietary technology to oxygenate blood for the INSPIRA ART (Gen 2). Thi
Inspira Technologies OXY B.H.N. Ltd. announced plans to report primary results for its core blood oxygenation technology, INSPIRA ART (Gen 2), within days. This innovative technology utilizes adaptive oxygenation methods to directly deliver oxygen into the blood, positioning the company to potentially disrupt the mechanical ventilation market. The anticipated FDA clearance for INSPIRA ART100, expected in early 2024, underscores the company's commitment to improving patient treatment options. Inspira's approaches aim to allow for awake treatment in patients without reliance on invasive ventilation methods.
Read more →QTEXInspira Announces Breakthrough Update: Nears First FDA 510(k) Approval, 3 U.S. Patents Approved, $546 million in Summary Distribution Agreements Ra'anana, Israel
Inspira Technologies announced significant advancements towards obtaining FDA 510(k) clearance for its INSPIRA ART100 device, anticipated in the first half of 2024. The company has also secured $546 million in distribution agreements and received three new patents. These developments position Inspira to reshape the mechanical ventilator market with its innovative blood oxygenation technology. However, the products are not yet approved for human use, and regulatory challenges could influence future progress.
Read more →QTEXInspira introduces high-end platform for bio-mimicking blood parameters for development and testing of core technologies Ra'anana, Israel
Inspira Technologies has launched a cutting-edge platform designed to mimic arterial and venous blood parameters for medical research and testing without requiring in vivo animal studies. This development aims to enhance the efficiency of testing their core technologies, including the HYLA Blood Sensor and VORTX system. The platform allows for real-time management of blood conditions and contributes to faster and more resource-effective research. However, it is important to note that these technologies have not yet been evaluated in human trials or approved by regulatory entities.
Read more →QTEXInspira Receives First Ever U.S. Patent Approval for an Orbiting Blood Oxygenation Delivery System 94% of the Claims Were Found to be Novel Ra'anana, Israel
Inspira Technologies OXY B.H.N. Ltd. has garnered its first U.S. patent approval for a novel orbiting blood oxygenation delivery system, a key component of the INSPIRA ART500 device. This technology aims to replace conventional mechanical ventilators by delivering oxygen directly into the blood without causing damage to blood cells. Designed to allow patients to remain awake during treatment, the device incorporates real-time blood parameter monitoring. The patent's approval marks a significant milestone for the company as it plans to enter the lucrative mechanical ventilation market.
Read more →QTEXInspira Technologies Collaborates with a Leading Israeli Medical Center for Clinical Evaluation of INSPIRA ART Device The parties have entered a non-binding Letter of Intent RA'ANANA, Israel
Inspira Technologies has signed a non-binding Letter of Intent with Shamir Medical Center in Israel for the clinical evaluation of its INSPIRA ART device. This collaboration aims to assess the device's integration within a clinical setting, focusing on its efficiency and overall impact on healthcare delivery. The project is contingent upon obtaining necessary approvals from the Israeli Ministry of Health and eventual formalizing of a detailed evaluation agreement. The partnership underscores Inspira's ambition to enhance life-support technologies while expanding its clinical deployment strategy.
Read more →QTEXInspira Technologies Signs Strategic Agreement to Enter Gulf States with Glo-Med for Deployment of 531 INSPIRA ART Devices The agreement to potentially provide Inspira Technologies with $32.6 million over a 5-year period
Inspira Technologies announced a strategic distribution agreement with Glo-Med Networks to deploy 531 INSPIRA ART devices across Gulf states, including Saudi Arabia, UAE, and Bahrain. The agreement has the potential to generate $32.6 million in revenue over the next five years, contingent upon regulatory approvals. The partnership capitalizes on Saudi Arabia's Vision 2030 healthcare initiatives, which aim to innovate and privatize the local healthcare sector. This agreement positions both companies to enhance patient care and improve market reach in the region.
Read more →QTEXInspira Announces Plans to Launch and Target Single-Use Disposable Blood Oxygenation Kit for a New Disposable Perfusion Market Opportunity The kit is being designed for the INSPIRA ART device series and is intended to be
Inspira Technologies OXY B.H.N Ltd. has announced plans to launch a single-use disposable blood oxygenation kit for its INSPIRA ART medical device series. The kit aims to be compatible with various life-support machines, potentially enhancing cost efficiency for hospitals. The company plans to submit the kit for FDA authorization in 2025 and believes it could expand their market presence significantly. Additionally, Inspira is set to receive FDA clearance for its INSPIRA ART100 device in the first half of 2024, which may further strengthen their position in the life support technology sector.
Read more →QTEXInspira Technologies Signs Letter of Intent with Northwestern Memorial Hospital in Chicago for Clinical Use of INSPIRA ART100 Device RA'ANANA, Israel, January 2 , 2024 - Inspira Technologies OXY B.H.N Ltd. (Nasdaq: IINN)
Inspira Technologies has signed a non-binding Letter of Intent with Northwestern Memorial Hospital to explore the clinical use of its INSPIRA ART100 device. This collaboration aims to assess how the device meets clinical needs and enhance healthcare delivery. Northwestern is expected to purchase disposables necessary for operating the device and provide valuable usage data. However, the agreement is contingent upon FDA clearance of the device and does not guarantee a formal collaboration.
Read more →QTEXInspira Announces $3.88 Million Registered Direct Offering Ra'anana, Israel
Inspira Technologies OXY B.H.N. Ltd. has announced a registered direct offering expected to raise $3.88 million by issuing 3,031,250 ordinary shares at a price of $1.28 per share. This financial move is part of the company's strategy to support its innovative life-support technologies. The offering is slated to close around December 28, 2023, pending satisfaction of customary closing conditions. The funds raised will be used primarily for working capital and general corporate purposes, showcasing Inspira's commitment to advancing healthcare technology.
Read more →QTEXInspira Announces 95% Accuracy Results for HYLA Blood Sensor, Planning FDA Submission for Clearance in 2024 RA'ANANA, Israel
Inspira Technologies has announced the achievement of 95% accuracy in its new HYLA Blood Sensor, which allows for continuous, real-time blood monitoring. This technology aims to replace traditional blood gas analyzers that require intermittent blood draws, potentially transforming operations in intensive care units. The company is planning to submit the sensor for FDA clearance under a 510(k) pathway in the second half of 2024. Additionally, there are plans to offer a standalone version of the Blood Sensor, further expanding its market reach.
Read more →QTEXIn Preparation for FDA Clearance and Device Deployment, Inspira has Appointed Dr. Dan Gorfil to Medical Advisory Board Ra'anana, Israel
Inspira Technologies has appointed Dr. Dan Gorfil to its medical advisory board as part of preparations for FDA clearance and device deployment. Dr. Gorfil, an expert in cardiac surgery, is expected to enhance the deployment of the INSPIRA ART100, which aims to transform life support technology. The company anticipates FDA approval for the device in the first half of 2024, reinforcing its commitment to innovative patient care solutions.
Read more →QTEXInspira Collaborates with Ennocure for Development of Proprietary Bio-Electronic Treatment to Prevent Associated Bloodstream Infections in ICU Patients Ra'anana, Israel
Inspira Technologies has announced a partnership with Ennocure MedTech to develop a bio-electronic treatment aimed at preventing bloodstream infections in ICU patients. This collaboration seeks to integrate Inspira's blood oxygenation technology with Ennocure's infection prevention solutions. The initiative is aimed at reducing complications associated with intravenous lines, which currently result in significant healthcare costs. The partnership is expected to enhance patient outcomes and potentially transform life-support treatments in intensive care environments.
Read more →QTEXInspira Technologies Reports Third Quarter 2023 Financial Results Ra'anana, Israel
Inspira Technologies OXY B.H.N. Ltd. announced its third quarter financial results for 2023, highlighting progress in its novel technology aimed at improving respiratory care. The company has made strides in securing distribution agreements and preparing for FDA approval for its ART100 device. Meanwhile, it reported a net loss of $8.28 million, up from $7.15 million from the previous year, and noted a significant decrease in cash reserves. CEO Dagi Ben-Noon expressed optimism about the company's advancements and the potential of its innovative approach to respiratory treatment.
Read more →QTEXInspira Announces Israeli Innovation Authority Grant for New VORTX Disposable Blood Oxygenation Technology Inspira's VORTX is a potential frontrunner in the $4 billion disposable blood oxygenator market Ra'anana, Israel
Inspira Technologies has announced the approval of a grant from the Israeli Innovation Authority for its innovative VORTX Disposable Blood Oxygenation Technology. This new technology, designed for compatibility with the INSPIRA ART product line, aims to mitigate typical complications associated with existing oxygenators. The grant supports 40% of the project's first-year budget, reflecting confidence in its market potential, estimated at $4 billion. However, the technology is still in development and has not yet been tested in human applications.
Read more →QTEXInspira Granted U.S. Patent for INSPIRA ART500 Medical Device This new patent advances Inspira's ability to enter into the Company estimated $20 billion market as a potential innovative frontrunner with planned global de
Inspira Technologies OXY BHN Ltd. has been granted a U.S. patent for its medical device, the INSPIRA ART500, which features a novel self-priming module. This advancement aims to enhance patient safety by reducing risks associated with mechanical ventilation systems. The company is targeting an estimated $20 billion market and has plans for global deployment, although the device has not yet completed human testing or received regulatory approval. CEO Dagi Ben-Noon views the patent as a significant milestone in building a global medical solution.
Read more →QTEXInspira Terminates ATM Program and Provides an Update Ra'anana, Israel
Inspira Technologies OXY B.H.N. Ltd. has announced the immediate termination of its at-the-market equity offering program. Despite the ongoing war in Israel, the company assures stakeholders that its operations remain unaffected. The company expresses condolences for the lives lost in the conflict while emphasizing its commitment to advancing acute respiratory care technologies, particularly the INSPIRA ART500. Caution regarding future uncertainties is noted due to the implications of the war.
Read more →QTEXInspira Enters into a Distribution Agreement in Central America with CIO MED GROUP The agreement to potentially generate $28 million, mainly in recurring revenues from disposable kits over a five year period following a
Inspira Technologies OXY BHN Ltd. has signed a distribution agreement with CIO MED GROUP to market its INSPIRA ART device line in Central America, potentially generating $28 million in recurring revenues over five years. The agreement focuses on devices designed to assist patients requiring acute respiratory care, specifically targeting the market need to minimize reliance on mechanical ventilation. However, the expected revenue is subject to regulatory approval, and other products remain in the development stage without human testing.
Read more →QTEXINSPIRA TECHNOLOGIES OXY B.H.N. LTD. INTERIM CONDENSED FINANCIAL STATEMENTS AS OF JUNE 30, 2023 UNAUDITED _______________________ ________________ ____________ INSPIRA TECHNOLOGIES OXY B.H.N. LTD. (UNAUDITED) TABLE OF CO
Inspira Technologies Oxy B.H.N. Ltd. reported its interim condensed financial statements for the period ending June 30, 2023. The company experienced a decline in total assets, decreased cash reserves, and an increased net loss compared to the same period in 2022. Their ongoing projects, including respiratory support technologies, remain unproven as they are not yet tested on humans and lack FDA approval. These financial findings reflect the challenges the company faces in sustaining its operations and advancing its product development.
Read more →QTEXInspira Technologies Unveils the INSPIRA ART Line of Medical Devices at the World's Largest Extracorporeal Life Support Conference The ELSO conference brings together healthcare institutions, researchers, and industry pa
Inspira Technologies announced the introduction of its INSPIRA ART line of medical devices at the ELSO conference, focusing on improving acute respiratory care. The line includes the INSPIRA ART100, designed for cardio-pulmonary bypass procedures, and the INSPIRA ART500, aimed at providing solutions for severe breathing difficulties. The company aims to gain FDA clearance for the INSPIRA ART100 in the first half of 2024 and has established a partnership with Perfusion Solution, Inc. to enhance its market entry strategy. However, the devices have yet to undergo human testing and lack FDA approval.
Read more →QTEXInspira TM Announces 510(k) FDA Submission of INSPIRA TM ART100 Towards Commercialization Management estimates FDA clearance within approximately 6 months Ra'anana, Israel
Inspira Technologies OXY BHN Ltd. has announced the submission of its cardio-pulmonary bypass device, INSPIRA ART 100, to the FDA for clearance via the 510(k) pathway. The company anticipates receiving approval within six months, targeting the first half of 2024. This innovative device aims to reduce reliance on mechanical ventilation and aims to transform external breathing assistance for millions of patients requiring ventilation each year. Inspira plans to prepare for global deployment of its systems following FDA clearance.
Read more →QTEXInspira Signs Agreement Expansion with Innovimed for Clinical Trials of INSPIRA ART Respiratory Medical Devices The extended agreement covers any European country Ra'anana, Israel, August 29 , 2023 - Inspira Technologies
Inspira Technologies has expanded its agreement with Innovimed to conduct clinical trials for their INSPIRA ART medical devices across all European countries. This agreement supplements their previously established partnership and has the potential to generate over $130 million in revenue over the next seven years. The technology aims to improve acute respiratory care by reducing reliance on invasive mechanical ventilation systems, thus lowering mortality rates among patients. Inspira's CEO emphasized the importance of this agreement in enhancing their recognition within the European Union market ahead of future product commercialization.
Read more →QTEXInspira Technologies Reports Second Quarter 2023 Financial Results As of
Inspira Technologies released its financial results for Q2 2023, revealing an increase in net loss to $5.9 million. The company is progressing towards submitting its INSPIRA ART100 for FDA clearance and has reduced research and development expenses. Additionally, preparations are underway for showcasing their innovations at the upcoming ELSO conference. Despite the financial challenges, Inspira remains committed to developing advanced respiratory care technologies.
Read more →QTEXINSPIRA TM ART100 Completes Usability Study in Boston Massachusetts, U.S. Ra'anana, Israel
Inspira Technologies has completed a Usability Study in Boston for its INSPIRA ART100 device, which supports cardiac and pulmonary health by enriching blood with oxygen and removing carbon dioxide. The study involved healthcare professionals evaluating the device in realistic settings. CEO Dagi Ben Noon expressed commitment to revolutionizing the medical device industry with innovative technology. However, it is noted that the products have not yet been tested on humans or received regulatory approval.
Read more →QTEXInspira Technologies Receives Certification of Medical Devices Quality Management Systems, Another Step Towards EU Regulatory Approval Ra'anana, Israel
Inspira Technologies OXY B.H.N. Ltd. has achieved ISO 13485:2016 certification, pivotal for gaining EU regulatory approval for its medical devices. This certification underscores the company's commitment to quality management standards in the medical device industry. The company develops innovative Augmented Respiration Technology aimed at improving patient outcomes in respiratory care; however, their products remain untested in human trials and lack regulatory approval.
Read more →QTEXInspira Technologies Enters into Collaboration Agreement with U.S.-Based Perfusion Solution Inc. Perfusion Solution, Inc. is a leading U.S.-based company that provides a platform of advanced medical devices, training and
Inspira Technologies has announced a collaboration agreement with Perfusion Solution Inc. to combine their INSPIRA ART100 with Perfusion Solution's extensive commercial infrastructure in the U.S. The partnership aims to enhance patient outcomes in acute respiratory care, especially during open-heart surgeries. However, the product has not yet been tested in humans, and its commercial success hinges on forthcoming FDA regulatory approval.
Read more →QTEXInspira Technologies Unveils Investor Deck Showcasing Revolutionary Advancement in Acute Respiratory Care Ra'anana, Israel
Inspira Technologies has unveiled an investor deck presenting innovations in acute respiratory care, notably the INSPIRA ART500 technology. This device aims to enhance patient care by providing respiratory support without the need for mechanical ventilators. The company anticipates submitting the device for FDA approval and has identified substantial market opportunities. CEO Joe Hayon emphasized the importance of this technology in reshaping respiratory healthcare and the company's ongoing commitment to innovation.
Read more →QTEXInspira Technologies Appoints Dr. Nir as Chief Medical Officer Dr. Nir is a clinical strategy expert with market experience Ra'anana, Israel
Inspira Technologies has appointed Dr. Adi Rizansky Nir as their new Chief Medical Officer. With her extensive background in clinical strategy and healthcare leadership, Dr. Nir is expected to play a pivotal role in enhancing medical operations and strategic initiatives at Inspira. Her responsibilities will include overseeing the upcoming FDA submission and clinical trial planning. The company's focus on revolutionizing acute respiratory care treatments is anticipated to benefit from her expertise.
Read more →QTEXInspira Technologies Reports First Quarter 2023 Financial Results As of
Inspira Technologies reported its financial results for the first quarter of 2023, revealing $11.5 million in cash and equivalents. The company is working towards FDA regulatory submission for the New ALICE Device and has ongoing clinical studies for its non-invasive blood sensor at Sheba Medical Centre. However, the company reported a net loss of $3.0 million, significantly greater than the $1.3 million loss from the same period last year. Shareholders' equity has also decreased to $10 million, raising concerns about financial stability.
Read more →QTEXInspira Technologies will Reveal the New ALICE TM Device at the World's Largest Extracorporeal Life Support Conference The ELSO conference is a consortium of healthcare institutions, researchers, and industry partners Ra
Inspira Technologies is set to unveil its new ALICE device at the upcoming ELSO conference in Seattle, aimed at revolutionizing acute respiratory care. The device, which facilitates extracorporeal blood circulation for cardiac and pulmonary support, is designed to improve user experience with its innovative features. The company plans to initiate commercial engagements and submit the device to the FDA for approval under the 510(k) pathway. However, it is important to note that the device has not yet been tested in humans and carries certain regulatory uncertainties.
Read more →QTEXInspira Technologies is Developing the VORTX TM Blood Oxygenator, a Unique Technology for Saturating Blood With Oxygen and Removing Carbon Dioxide Total addressable market is currently estimated at $1.16 billion Ra'anana
Inspira Technologies is advancing the development of the VORTXTM Blood Oxygenator, which aims to improve blood oxygen saturation and carbon dioxide removal. The device targets the substantial market for extracorporeal procedures valued at approximately $1.16 billion. With innovations expected to enhance hemodynamic performance, the VORTXTM could transform the existing blood oxygenator landscape. However, the product has yet to undergo human testing and requires FDA review and approval before it can enter the market.
Read more →QTEXInspira Technologies Reports Fourth Quarter 2022 and Full Year Financial Results As of
Inspira Technologies has reported its financial results for the fourth quarter and full year of 2022. The company highlights a cash position of $13.9 million and a reduced net loss of $10.3 million, down from $17 million the previous year. The firm is progressing with its clinical studies for the INSPIRA ART system, with plans for FDA submission in the latter half of 2023. Despite these advances, Inspira also notes a significant decline in total cash and shareholder equity compared to the previous year.
Read more →QTEXInspira TM Technologies Announces First In Human of HYLA TM Blood Sensor in Clinical Study First use of HYLA in a patient undergoing open-heart surgery at Sheba Medical Center in Israel Ra'anana, Israel
Inspira Technologies OXY B.H.N. Ltd. has announced the first use of its HYLA Blood Sensor in a human patient undergoing open-heart surgery at Sheba Medical Center in Israel. This innovative non-invasive optical sensor is designed to continuously monitor key blood parameters during advanced medical procedures such as VV-ECMO, VA-ECMO, and open-heart surgery. The ongoing clinical study aims to compare the HYLA sensor's measurements with traditional blood gas analyzers, gathering data to support future product design.
Read more →QTEXInspira TM Technologies Receives Approval from Sheba Medical Center to Conduct Clinical Study of the HYLA TM Blood Sensor The clinical study is planned for Q1-2023 to be performed on patients undergoing open-heart surger
Inspira Technologies OXY B.H.N. Ltd. has received approval from the Ethics Committee at Sheba Medical Center to conduct a clinical study of its HYLA blood sensor. This study, scheduled to begin in Q1-2023, will assess the sensor's ability to provide real-time measurements of blood parameters in patients undergoing open-heart surgery. The HYLA sensor promises to enhance patient monitoring and may lead to better medical interventions. This non-invasive device is part of a broader push to improve acute respiratory care technology.
Read more →QTEXCopyright 2018 - 2023 Inspira Technologies OXY B.H.N. LTD., All rights reserved 1 Investor Presentation NASDAQ: $IINN, $IINNW February 2023 Forward looking - Statements * The Inspira ART and the ART presented in this pre
Inspira Technologies has outlined its forward-looking statements regarding its innovative products aimed at revolutionizing acute respiratory care. Their technology, designed to assist compromised lung conditions while minimizing the need for invasive mechanical ventilation, targets a growing market, projected to reach approximately $27.6 billion by 2026. However, the presentation emphasizes the risks associated with unmet regulatory approvals and the inherent uncertainties in the company’s predictions and estimates, which could result in outcomes differing from expectations.
Read more →QTEXInspira TM Technologies Granted Patent by U.S. Patent Office for the INSPIRA TM ART System's Convertible Dual Lumen Cannula Device and Method of Use All 20 claims were found to be novel, with inventive step and industria
Inspira Technologies OXY B.H.N. Ltd. has received a patent from the U.S. Patent and Trademark Office for its convertible dual lumen cannula device, which is a crucial component of the INSPIRA ART system. This device allows for effective venous drainage and reinfusion of blood with reduced complications. The company plans to pursue additional patents internationally and potentially commercialize the device separately. The innovation aims to offer a more affordable solution in acute respiratory care, enabling patients to remain awake during treatments.
Read more →QTEXInspira Technologies Signs Strategic OEM Agreement with Terumo Cardiovascular Terumo Cardiovascular is a division of Terumo Corporation, a leading medical device company operating in 160+ countries and regions Ra'anana,
Inspira Technologies Signs Strategic OEM Agreement with Terumo Terumo Cardiovascular is a division of Terumo Corporation, a leading medical device company operating in 160+ countries and regions Ra'anana, Israel, December 27, 2022 - Inspira Technologies OXY B.H.N. Ltd. (Nasda
Read more →QTEXInspira TM Technologies Begins Manufacturing of the ALICE TM CPB Device, ahead of planned 2023 FDA submission The ALICE device is an important part of Inspira's market penetration strategy. Ra'anana, Israel
Technologies Begins Manufacturing of the ALICETM CPB Device, ahead of planned 2023 FDA submission ALICE device is an important part of Inspira's market penetration strategy. Israel, December 20, 2022 - Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the "Company" o
Read more →QTEXInspira Technologies Signs Agreement to Conduct Clinical Study of HYLA TM Blood Sensor The agreement with Sheba Medical Center, 10 th ranked hospital in the world*, to be the first site for the HYLA Blood Sensor's Clinic
Inspira Technologies Signs Agreement to Conduct Clinical Study of HYLATM Blood Sensor agreement with Sheba Medical Center, 10th ranked hospital in the world*, to be the first site for the Sensor's Clinical Study Ra'anana, Israel, December 14, 2022 - Inspira Technologies OXY
Read more →QTEXInspira Technologies Reports Third Quarter 2022 Financial Results As of
Inspira Technologies Reports Third Quarter 2022 Financial Results As of September 30, 2022, the Company had $16.2 million in cash, cash equivalents, and short-term bank deposits. Israel - Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the "Company" or "Inspira T
Read more →QTEXInspira TM Technologies Signs a Strategic Agreement in Europe to Potentially Provide $26.1 for Deployment of 1,364 HYLA TM Blood Sensors The agreement signed with Innovimed is over a 5-year period, subject to regulatory
Technologies Signs a Strategic Agreement in Europe to Potentially Provide $26.1 for Deployment of 1,364 HYLATM Blood Sensors The agreement signed with Innovimed is over a 5-year period, subject to regulatory approvals Ra'anana, Israel, November 22, 2022 - Inspira Technologi
Read more →QTEXInspira TM Technologies Granted Patent by the Israeli Patent Office for Key Safety Component for the INSPIRA TM ART System Ra'anana, Israel
InspiraTM Technologies Granted Patent by the Israeli Patent Office for Key Safety Component for the INSPIRATM ART System Ra'anana, Israel, November 10, 2022 - Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the "Company" or "Inspira Technologies"), a groundbreaking
Read more →QTEXINSPIRA TECHNOLOGIES OXY B.H.N. LTD. INTERIM CONDENSED FINANCIAL STATEMENTS AS OF JUNE 30, 2022 UNAUDITED INSPIRA TECHNOLOGIES OXY B.H.N. LTD. (UNAUDITED) TABLE OF CONTENTS Page Interim condensed statements of financial
INSPIRA TECHNOLOGIES OXY B.H.N. LTD. INTERIM CONDENSED FINANCIAL STATEMENTS INSPIRA TECHNOLOGIES OXY B.H.N. LTD. Page Interim condensed statements of financial position 1-2 Interim condensed statements of comprehensive loss 3 Interim condensed statements of changes in shar
Read more →QTEXInspira TM Technologies Performed HYLA TM Blood Sensor In-Vivo Study, in Preparation of Planned Human Studies The study team included leading ICU and respiratory specialists from Company's Scientific Advisory Board
Technologies Performed HYLATM Blood Sensor Study, in Preparation of Planned Human Studies study team included leading ICU and respiratory specialists from Company's Scientific Advisory Board Israel, September 7, 2022 - Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW)
Read more →QTEXInspira Technologies Reports Second Quarter 2022 Financial Results As of
Inspira Technologies Reports Second Quarter 2022 Financial Results As of June 30, 2022, the Company had $19.2 Ra'anana, Israel- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the "Company" or "Inspira Technologies"), a groundbreaking respiratory support technolo
Read more →QTEXCopyright 2018 - 2022 Inspira Technologies OXY B.H.N. LTD., All rights reserved August 2022 Investor Presentation Forward looking - Statements This presentation of Inspira TM Technologies Oxy B . H . N . Ltd . ("Inspira
Fellowships in ECMO at the NHS, UK and cardiothoracic anesthesia at Harefield Hospital` Prof. Eddy Fan Intensivist & ECMO Advisor Medical director of the extracorporeal life support program at the Toronto General Hospital. Intensivist at the University Health Network/Mount Sinai
Read more →QTEXInspira Technologies Reveals Next Generation Liby ECMO, an Extracorporeal Membrane Oxygenation System, Targeting a $531 Million Global ECMO Market
Technologies Reveals Next Generation Liby ECMO, an Extracorporeal Membrane Oxygenation System, Targeting a $531 Million Global Israel, July 11, 2022 - Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the "Company" or "Inspira Technologies") introduces today the "Liby
Read more →QTEXInspira Technologies Signs Strategic Agreement in U.S. to potentially provide $59 million for Inspira for deployment of 3,889 HYLA Blood Sensors The agreement signed with Glo-Med Networks for the potential deployment of
Inspira Technologies Signs Strategic Agreement in U.S. to potentially provide $59 million for Inspira for deployment of 3,889 HYLA Blood Sensors The agreement signed with Glo-Med Networks for the potential deployment of HYLA Blood Sensors over a 3-year period, subject to re
Read more →QTEXInspira Technologies Develops a Non-Invasive Blood Sensor Designed to Alert Real-Time Change in Patients - Potentially Targets $2.5 Billion ABG Market HYLA blood sensor intends to reduce the need for actual blood samples
Inspira Technologies Develops a Non-Invasive Blood Sensor Designed to Alert Real-Time Change in Patients - Potentially Targets $2.5 Billion ABG Market HYLA blood sensor intends to reduce the need for actual blood samples to be taken from patients Ra'anana, Israel- Inspira Tec
Read more →QTEXInspira Technologies Announces First Quarter 2022 Financial Results As of
Technologies Announces First Quarter 2022 Financial Results of March 31, 2022, the Company had $21.7 million in cash Israel- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the "Company" or "Inspira Technologies"), a groundbreaking respiratory support technology co
Read more →QTEXInspira Technologies Announces Deployment Agreement in the Israeli Market to Target $15M The Agreement is for a 7-year Period, Subject to Regulatory Approval
Inspira Technologies Announces Deployment Agreement in the Israeli Market to Target $15M The Agreement is for a 7-year Period, Subject to Regulatory Approval RA'ANANA, Israel, Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) ("Inspira" or the "Company") announced t
Read more →QTEXInspira Technologies Releases Q4 & FY2021 Financial Results
Inspira Technologies Releases Q4 & FY2021 RA'ANANA, Israel, Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW),has released its financial results for 2021 by posting an update on its Investor Relations website. Please click here to view the CEO update. Investor Relati
Read more →QTEXInspira Technologies Appointed an Expert in the Field of Artificial Lung as the New Chief Technology Officer (CTO) - Daniella Yeheskely-Hayon PhD Ra'anana, Israel
Inspira Technologies Appointed an Expert in the Field of Artificial Lung as the New Chief Technology Officer (CTO) - Daniella Yeheskely-Hayon PhD Israel, February 3, 2022 - Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the "Company" or "Inspira Technologies"), a
Read more →QTEXRevolutionizing Acute Respiratory Care February 2022 Copyright 2018 - 2022 Inspira Technologies OXY B.H.N. LTD., All rights reserved Nasdaq: IINN / IINNW 2 Copyright 2018 - 2022 Inspira Technologies OXY B.H.N. LTD., All
Respiratory Failure The Unmet Need Market Potential The U.S. Market Multiple trends propelling the market COVID - 19 and growing medical community experience with extracorporeal respiratory systems is expected to accelerate market adoption Co p y r i g ht 2018 - 2 0 2 2 I nsp i
Read more →QTEXInspira Technologies Signs a Strategic Agreement in the U.S. to Target $212 Million for Inspira Over a 7-Year Period, Subject to Regulatory Approvals The agreement is with U.S. based Glo-Med Networks for the potential de
Technologies Signs a Strategic Agreement in the U.S. to Target $212 Million for Inspira Over a 7-Year Period, Subject to is with U.S. based Glo-Med Networks for the potential deployment of 2,121 ART Systems in 6 U.S. States Israel, January 31, 2022 - Inspira Technologies OXY
Read more →QTEXInspira Technologies Has Listed an FDA Class I 510(k) Exempt component of the ART system Ra'anana, Israel
Technologies Has Listed an FDA Class I 510(k) Exempt component of the ART system Israel, January 28, 2022 - Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the "Company" or "Inspira Technologies"), a groundbreaking respiratory support technology company, announced
Read more →QTEXProfessor Daniel Brodie, the President of the International Extracorporeal Organization (ELSO) and Director of Critical Care from New-York Columbia - Presbyterian Hospital, Has Joined Inspira Technologies' Advisory Board
Professor Daniel Brodie, the President of the International Extracorporeal Organization (ELSO) and Director of Critical Care from New-York Columbia - Presbyterian Hospital, Has Joined Inspira Technologies' Advisory Board Israel, January 19, 2022 - Inspira Technologies OXY B.H.
Read more →QTEXAbout ART System This presentation contains express or implied forward - looking statements pursuant to U.S. Federal securities laws. For example, the Company is using forward - looking statements when it discusses the A
A R T ' s P r opri e t a r y H e m o - P r o t ec t i v e Flow Technology Features Bloo d p r o t e ct io n 1 - 1.5 liters of blood are being enriched with oxygen, rebalance patient's oxygen saturation levels in minutes A R T ' s d es i g n e d f e a t u r e s Hemolysis reduction
Read more →QTEXAMENDED ARTICLES THE COMPANIES LAW, 1999 A LIMITED LIABILITY COMPANY ARTICLES OF ASSOCIATION OF INSPIRA TECHNOLOGIES OXY B.H.N. LTD. Preliminary 1. Definitions; Interpretation . (a) In these Articles, the following terms
THE COMPANIES LAW, 1999 A LIMITED LIABILITY COMPANY ARTICLES OF ASSOCIATION INSPIRA TECHNOLOGIES OXY B.H.N. LTD. (a) In these Articles, the following terms (whether or not capitalized) shall bear the meanings set forth opposite to them respectively, unless inconsistent with
Read more →QTEXInspira Technologies Signs Strategic Agreement with Innovimed for the Potential Deployment of 1,522 ART Systems in Poland, Czech Republic & Slovakia The agreement to target $108 million for Inspira Technologies over a 7-
Technologies Signs Strategic Agreement with Innovimed for the Potential Deployment of 1,522 ART Systems in Poland, Czech Republic & Slovakia to target $108 million for Inspira Technologies over a 7-year period, subject to regulatory approvals Israel, December 9 , 2021 - Inspira
Read more →QTEXInspira Technologies: Professor Eddy Fan, Expert in Critical Care Medicine and Extracorporeal Support, Joined Inspira's Scientific Advisory Board Prof. Fan currently serves as the medical director of the extracorporeal l
Technologies: Professor Eddy Fan, Expert in Critical Care Medicine and Extracorporeal Support, Joined Inspira's Scientific Advisory Board Fan currently serves as the medical director of the extracorporeal life support program at the Toronto General Hospital Israel, November
Read more →QTEXInspira Technologies Announces 2021 Third Quarter Financial Results In October 2021, Company increases cash balance by $9.4 Million due to investors Exercising Warrants; As of November 1, the company has $ 26 million in
Inspira Technologies Announces 2021 Third Quarter Financial Results In October 2021, Company increases cash balance by $9.4 Million due to investors Exercising Warrants; As of November 1, the company has $ 26 million in cash Israel, November 23, 2021 - Inspira Technologies OX
Read more →QTEXDr. Stephane Ledot, an Expert in Critical Care and Anesthesia, Has Joined Inspira Technologies' Scientific Advisory Board In the last few years, Dr. Ledot has served as the director of critical care and ECMO service and
Stephane Ledot, an Expert in Critical Care and Anesthesia, Has Joined Inspira Technologies' Scientific Advisory Board the last few years, Dr. Ledot has served as the director of critical care and ECMO service and as a senior anesthetic at the Royal Brompton & Harefield hospital
Read more →QTEXINSPIRA TECHNOLOGIES OXY B.H.N. Ltd. Notice of EXTRAORDINARY General Meeting of shareholders Notice is hereby given that an Extraordinary General Meeting of Shareholders (the " Meeting ") of Inspira Technologies Oxy B.H.
TECHNOLOGIES OXY B.H.N. Ltd. of EXTRAORDINARY General Meeting of shareholders Notice is hereby given that an Extraordinary General Meeting of Shareholders (the "Meeting") of Inspira Technologies Oxy B.H.N. Ltd. ("Inspira Technologies" or the "Company") will be held on Decembe
Read more →QTEXINSPIRA TECHNOLOGIES OXY B.H.N. LTD. INTERIM CONDENSED FINANCIAL STATEMENTS AS OF JUNE 30, 2021 UNAUDITED _______________________ ________________ ____________ INSPIRA TECHNOLOGIES OXY B.H.N. LTD. (UNAUDITED) TABLE OF CO
INSPIRA TECHNOLOGIES OXY B.H.N. LTD. INTERIM CONDENSED FINANCIAL STATEMENTS _______________________ INSPIRA TECHNOLOGIES OXY B.H.N. LTD. Page Interim condensed statements of financial position 1-2 Interim condensed statements of comprehensive loss 3 Interim condensed stat
Read more →QTEXInspira Technologies Enters Europe: Signs a Strategic Agreement With Waas Group for the Deployment of 1,040 ART Systems in Spain and Portugal The agreement to potentially provide $66 million to Inspira Technologies over
Technologies Enters Europe: a Strategic Agreement With Waas Group for the Deployment of 1,040 ART Systems in Spain and Portugal agreement to potentially provide $66 million to Inspira over a 7-year period, subject to regulatory approval Israel, October 26, 2021 - Inspira Tec
Read more →QTEXRevolutionizing Acute Respiratory Care O c t ob er 2021 Copyright 2018 - 2021 Inspira Technologies OXY B.H.N. LTD., All rights reserved Forward looking - Statements 2 Copyright 2018 - 2021 Inspira Technologies OXY B.H.N.
Prior to joining the interdepartmental program of critical care at the University of Toronto, he served as a senior intensive care physician at a leading Israeli hospital - the Tel Aviv Sourasky Medical Center (Ichilov), where he initiated its institutional extracorporeal membran
Read more →QTEXInspira Technologies' "Artificial Lung" to Acquire a Digital Edge: The Company Contracted GlobalLogic, a Hitachi Group Company, for Advanced Digital Product Engineering Services Ra'anana, Israel /
Technologies' "Artificial Lung" to Acquire a Digital Edge: Company Contracted GlobalLogic, a Hitachi Group Company, for Advanced Digital Product Engineering Israel / September 22, 2021/ -- Inspira Technologies OXY B.H.N. Ltd ("Inspira Technologies" or the "Company") (Nasdaq:
Read more →QTEXInspira Technologies OXY B.H.N Ltd. (IINN,IINNW) P 1 roprietary - Inspira Technologies Oxy B.H.N. Ltd. This presentation of Inspira Technologies Oxy B . H . N . Ltd . (the "Company" or "Inspira") contains "forward - look
Inspira Technologies OXY B.H.N Ltd. (IINN,IINNW) P 1 roprietary - Inspira Technologies Oxy B.H.N. Ltd. This presentation of Inspira Technologies Oxy B . H . N . Ltd . (the "Company" or "Inspira") contains "forward - looking statements" within the meaning of the Private Securitie
Read more →QTEXInspira Technologies Reached Important Milestone as It Completed a Pump Bench Study The "External Lung" pump is a core component of the ART device Ra'anana, Israel /
Technologies Reached Important Milestone as It Completed a Pump Bench Study "External Lung" pump is a core component of the ART device Israel / August 18, 2021/ -- Inspira Technologies OXY B.H.N. Ltd ("Inspira Technologies" or the "Company"), a specialty medical device company
Read more →QTEXInspira Technologies Announces First Half 2021 Financial Results and Provides Business Update Ended the first half of 2021 with cash and cash equivalents of $4,355,000 On the path to develop potential strategic collabora
Technologies Announces First Half 2021 Financial Results and Provides Business Update Israel / August 13, 2021/ -- Inspira Technologies OXY B.H.N. Ltd (Nasdaq: IINN, IINNW) (the "Company" or "Inspira"), a specialty medical device company engaged in the research, development, ma
Read more →QTEXInspira Technologies Expands Board of Directors to Accelerate Company's Go-to-Market Efforts CPA Lior Amit to join the board of directors Ra'anana, Israel /
Inspira Technologies Expands Board of Directors to Accelerate Company's Go-to-Market Efforts CPA Lior Amit to join the board of directors Israel / August 10, 2021/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the "Company"), a specialty medical device comp
Read more →QTEXInspira Expands Medical Advisory Board as part of future expansion into North American Market Dr. Dekel Stavi is an Intensive Care Physician at the Interdepartmental Division of Critical Care Medicine, University of Toro
Inspira Expands Medical Advisory Board as part of future expansion into North American Market Dr. Dekel Stavi is an Intensive Care Physician at the Interdepartmental Division of Critical Care Medicine, University of Toronto Ra'anana, Israel, July 26, 2021 - Inspira Technol
Read more →QTEXInspira Technologies and Ben-Gurion University Have Developed a Platform Designed to Prevent Blood Clotting in Inspira's ART System An oxygen releasing microbubble platform Ra'anana, Israel
Inspira Technologies and Ben-Gurion University Platform Designed to Prevent Blood Clotting in Inspira's ART System An oxygen releasing microbubble platform Ra'anana, Israel, July 19, 2021 - Inspira Technologies Oxy B.H.N. Ltd. (Nasdaq: IINN, IINNW), a breakthrough respiratory
Read more →QTEXInspira Technologies OXY B.H.N. Ltd Announces Closing of Initial Public Offering Ra'anana, Israel /
Inspira Technologies OXY B.H.N. Ltd Announces Closing of Initial Public Offering Ra'anana, Israel / July 16, 2021/ -- Inspira Technologies OXY B.H.N. Ltd (the "Company"), a specialty medical device company engaged in the research, development, manufacture, and marketing of p
Read more →QTEXInspira Technologies OXY B.H.N. Ltd Announces Pricing of Initial Public Offering Ra'anana, Israel /
Technologies OXY B.H.N. Ltd Announces Pricing of Initial Public Offering Israel / July 13, 2021/ -- Inspira Technologies OXY B.H.N. Ltd (the "Company"), a specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary respirator
Read more →Competitive Position
How QTEX ranks across every disease it competes inCompetitive Position is a premium feature
See how QTEX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial